The global cardiogenic shock market has been experiencing significant growth, driven by advancements in treatment modalities, increasing prevalence of cardiovascular diseases, and a concerted focus on improving patient outcomes. The global cardiogenic shock market was valued at US$ 3.29 Billion in 2021 and is expected to reach US$ 6.32 Billion by 2032, expanding at a CAGR of 6.2% over the 2022...